The 2026 HHS peptide policy: what it allows, and what it doesn’t.

In late October 2026, the U.S. Department of Health and Human Services announced an interim policy that lets licensed physicians prescribe six peptides that previously couldn't be compounded legally. Here's what changed, what didn't, and how we handle it at Javid.

What the policy does

HHS announced an interim enforcement-discretion policy on October 28, 2026, published in the Federal Register on October 30. It says FDA won't take action against state-licensed 503A compounding pharmacies, federal facilities, or licensed physicians who compound six peptide bulk substances, as long as specific conditions are met. The six peptides, and the routes the policy covers, are:

• BPC-157: subcutaneous, intramuscular, oral, or topical
• TB-500: subcutaneous or intramuscular injection
• Epitalon: subcutaneous or intramuscular injection, in intermittent courses
• Semax: intranasal
• KPV: topical or oral
• MOTS-c: subcutaneous or intramuscular injection

The conditions that come with it

• One patient, one prescription. Each product must be compounded under a valid prescription for a specific patient. It isn't for office stock or bulk sale.
• One active ingredient. A product can contain only one of the six. Pre-mixed blends aren't covered.
• 503A only. It covers state-licensed compounding pharmacies, not 503B outsourcing facilities.
• Quality controls. Ingredients must come from FDA-registered manufacturers that follow good manufacturing practices and supply a certificate of analysis, and the policy also sets labeling and adverse-event reporting requirements.

What it doesn't do

The policy is not FDA approval. None of the six peptides has been through the approval process for any use, and the policy doesn't establish that any of them is safe or effective for a particular condition. Most of the evidence behind them comes from laboratory, animal, or small human studies.

The policy is also interim. HHS described it as a bridge while FDA continues rulemaking on which bulk substances 503A pharmacies may use, and it can be revised or withdrawn if safety or quality problems appear. A peptide that's lawfully compoundable today may not stay that way.

How we approach it at Javid

We treat these six peptides the way we treat any off-label or compounded option. We discuss them openly, weigh the evidence and the alternatives, and prescribe only when one is appropriate for you after an evaluation. FDA-approved therapies remain our default. If a peptide is part of your plan, it's prescribed for you alone, made by a state-licensed 503A pharmacy, and followed with your labs and visits.

If you're considering peptides, bring your questions to a visit. Our Peptide Atlas lists 81 peptides by body system and regulatory status, so you know what you're looking at before you ask.

This article is general education, not medical advice, and doesn’t establish a physician–patient relationship. Rules can change after the date above.